Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its price objective reduced by B. Riley from $4.00 to $3.00 in a research note released on Friday,Benzinga reports. They currently have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback